Navigation Links
U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
Date:3/13/2008

- DAPTACEL vaccine is licensed for the entire immunization series to

protect against diphtheria, tetanus, and pertussis -

SWIFTWATER, Pa. and LYON, France, March 13 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed DAPTACEL(R) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) to be administered as a fifth consecutive diphtheria, tetanus, and acellular pertussis (DTaP) vaccine dose for children 4 years through 6 years of age for the prevention of diphtheria, tetanus, and pertussis.

In 2002, DAPTACEL vaccine was licensed by the FDA for four consecutive doses, currently administered at 2, 4, 6, and 15 to 20 months of age. The approval of the fifth consecutive dose of DAPTACEL vaccine completes the FDA license for the entire five-dose DAPTACEL vaccine series enabling health-care professionals to administer the same brand of DTaP vaccine for the series as recommended by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP).

The fifth consecutive dose of DAPTACEL vaccine also provides a convenient fit with the CDC's recommended immunization schedule. According to the ACIP, AAP, and AAFP recommendations, these five doses should be administered before 7 years of age.

The safety of DAPTACEL vaccine was demonstrated in a clinical trial involving 487 children across 22 different trial sites who received DAPTACEL vaccine as a fifth consecutive dose. Out of the subjects included in the safety examination in this study, 98 percent (477/487) completed the 180-day safety follow-up after receiving the fifth dose. Of the 10 children (2 percent of 487) who did not complete the 180-day follow-up, 3 were lost to follow-up, 6 were discontinued due to no
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
5. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
6. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
7. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
8. Syngenta Licenses Chromatin Gene Stacking Technology
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. Prometheus Licenses COLAL-PRED(R) From Alizyme
11. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... 11 , - TB-402 Shows Clear Promise ... Thromboembolic Disorders., ThromboGenics NV (Euronext Brussels:THR), a ... that the results of the,first Phase I trial ... Society of Hematology (ASH) 49th Annual Meeting in ...
... The Perrigo Company,(Nasdaq: PRGO ; TASE) announced today ... final approval to Dexcel Pharma,Technologies, Ltd. for 20 mg ... this product for the store brand,over-the-counter (OTC) market in ... during the first quarter of calendar year 2008,with full ...
... Tutogen Medical, Inc.,(Amex: TTG ), a leading manufacturer of ... tissue, today announced,financial results for the fiscal year and fourth ... Highlights for the fiscal year include:, -- Total ... of dental products increased 38% in fiscal year 2007; ...
Cached Biology Technology:ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 2Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:7/11/2014)... 2014 Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
(Date:7/11/2014)... the hippocampus, the marginal division of the striatum ... is the impact degree of substance P in ... function? Yan Yu and his team, College of ... immunofluorescence staining, that substance P receptor, neurokinin 1 ... marginal division of normal rats. Unilateral or bilateral ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... A UC Riverside-led research team has found that as ... they do so by increasing only that segment of ... of an individual to contribute offspring to the next ... have studied for long, the researchers found that guppies ...
... to treat diseases such as cystic fibrosis, reduce bacterial ... and the University of Texas at Austin has determined ... be pivotal in preventing certain bacterial infections in plants, ... the Proceedings of the National Academy of Sciences. ...
... the prevailing belief that adult brain cells don't grow, a ... in the Dec. 27 issue of Public Library of Science ... occur in mature brains. , This finding means that ... to replace ones damaged by disease or spinal cord injury, ...
Cached Biology News:Fish evolve a longer lifespan by evolving a longer reproductive period, researchers find 2Scientists determine structure of enzyme that disrupts bacterial virulence 2MIT researcher finds neuron growth in adult brain 2MIT researcher finds neuron growth in adult brain 3
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
Sterile, individually wrapped, 4mm Cuvettes...
... fully flexible quadrupole MS detector optimized for ... 1-D and 2-D LC, as well as ... a drying gas system to create a ... for low-to-medium polarity compounds, while providing for ...
Biology Products: